Core Viewpoint - L'Oréal is actively expanding its market presence through acquisitions and investments, particularly focusing on the medical aesthetics sector, in response to slowing growth in its core beauty business [2][9]. Group 1: Acquisitions and Investments - L'Oréal has acquired an additional 10% stake in Galderma, increasing its ownership to 20%, following an initial investment in 2024 [3]. - The company recently invested €4 billion to acquire beauty licenses for several luxury brands from Kering Group, including Creed and others, with a total agreement value of €40 billion [6]. - L'Oréal has also invested in domestic skincare brands, including a stake in Naturals and a minority investment in LAN [6]. Group 2: Medical Aesthetics Focus - The acquisition of Galderma is seen as a strategic move to enhance L'Oréal's presence in the medical aesthetics market, which includes skincare and aesthetic treatments [4]. - Galderma's product offerings, such as Restylane and Sculptra, have gained regulatory approval in China, indicating a strong market potential [3]. - L'Oréal's CEO emphasized the importance of the aesthetics business as a key extension of their core beauty operations, aiming to deepen collaboration with Galderma [3]. Group 3: Financial Performance - L'Oréal's sales for the first three quarters of the year reached €32.8 billion, reflecting a growth rate of approximately 1.2%, a decline from the previous year's 6% [9]. - The company's sales in the North Asia market, including China, saw a decline of 1.1% to €5.39 billion in the first half of 2025 [9]. - Overall, L'Oréal's projected sales growth for 2024 is 5.1%, significantly lower than the growth rates of 18.5% and 7.6% in 2022 and 2023, respectively [9].

Core Viewpoint - Aimeike Technology Development Co., Ltd. reported a decline in revenue and net profit for Q1 2025, indicating challenges in the medical aesthetics industry amid increased competition and regulatory pressures [1][2]. Financial Performance - In Q1 2025, Aimeike achieved revenue of 663 million yuan, a year-on-year decrease of 17.90% - The net profit attributable to shareholders was 444 million yuan, down 15.87% year-on-year [1]. Market Trends - The non-surgical light medical aesthetics market is expected to grow at a rate of 10% in 2024, down from previous highs in 2023, as the industry transitions from "technical dividends" to "comprehensive competitiveness" [2]. - Increased competition has led to a downward trend in product prices, while consumer decision-making periods for high-end medical aesthetics have lengthened due to macroeconomic uncertainties [2]. Strategic Positioning - Aimeike is one of the few leading companies not actively participating in price wars, maintaining a gross margin of 93.85% in Q1 2025, a slight decrease of 0.7 percentage points year-on-year [4]. - The company emphasizes brand value and product quality over short-term price advantages, aiming for long-term market resilience [4]. Research and Development - Aimeike's R&D expenses reached 58.54 million yuan in Q1 2025, accounting for 8.82% of revenue, an increase of 1.65% year-on-year, reflecting a strong commitment to innovation [4]. - Ongoing projects focus on cutting-edge areas such as regenerative materials and collagen, which may not yield immediate sales but are expected to drive long-term growth [4]. Product Expansion - Aimeike has received approval for a new product, a medical-grade gel for jawline filling, which will soon be launched, marking it as the third approved product in this category in China [5]. - The company is also expanding its market presence through the acquisition of 85% of South Korea's REGEN Biotech Inc. for approximately 190 million USD, positioning itself as the only domestic company with two regenerative medical aesthetics products [5].